TABLE 2.
Etiologic microorganisms in patients receiving and not receiving aminoglycosides as empirical therapy
| Microorganism | No. (%; n = 4,863) | No. (%) receiving: |
OR (95% CI) | P | |
|---|---|---|---|---|---|
| Combination therapy (n = 678) | β-Lactams only (n = 4,185) | ||||
| Non-ESBL Escherichia coli | 2,737 (56) | 248 (37) | 2,489 (60) | 0.4 (0.3-0.5) | <0.0001 |
| ESBL E. coli | 150 (3) | 28 (4) | 122 (3) | 1.4 (0.9-2) | 0.09 |
| Non-ESBL Klebsiella pneumoniae | 483 (10) | 63 (9) | 420 (10) | 0.9 (0.7-1.2) | 0.5 |
| ESBL K. pneumoniae | 83 (2) | 20 (3) | 63 (2) | 2 (1.2-3) | 0.007 |
| Proteus mirabilis | 128 (3) | 10 (2) | 118 (3) | 0.5 (0.3-1) | 0.04 |
| Salmonella spp. | 124 (3) | 15 (2) | 109 (3) | 0.9 (0.5-2) | 0.5 |
| AmpC Enterobacteriaceaea | 408 (8) | 82 (12) | 326 (8) | 1.6 (1.3-2) | 0.0002 |
| P. aeruginosa | 462 (10) | 143 (21) | 319 (8) | 3 (2.6-4) | <0.0001 |
| Other nonfermentersb | 156 (3) | 51 (8) | 105 (3) | 3 (2-5) | <0.0001 |
| Miscellaneousc | 132 (3) | 18 (3) | 114 (3) | 0.9 (0.6-1.6) | 0.8 |
a
Includes Enterobacter (n = 230), S. marcescens (n = 68), Citrobacter (n = 58), and Proteeae (n = 52) isolates.
b
Includes Acinetobacter baumannii (n = 57), Strenotrophomonas maltophilia (n = 50), Burkholderia cepacia (n = 8), and Pseudomonas (n = 41) isolates.
c
Includes Haemophilus (n = 37), Neisseria (n = 25), Aeromonas (n = 20), and other (n = 50).